[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@GermanBiotech Avatar @GermanBiotech German Biotech

German Biotech posts on X about $4587t, $pptdf, tokyo, tokyo stock exchange the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence finance XX% stocks XX% travel destinations XX% exchanges XX%

Social topic influence $4587t 20%, $pptdf #1, tokyo 10%, tokyo stock exchange 10%, $pfe #245, $lly #154, $mtsr #64, $nvo #202, investment 5%, $ptgx X%

Top accounts mentioned or mentioned by @dedwng @mhdksafa @sunrgu

Top assets mentioned Pfizer, Inc. (PFE) Eli Lilly and Company (LLY) Metsera, Inc. Common Stock (MTSR) Novo-Nordisk (NVO) Protagonist Therapeutics, Inc (PTGX) Johnson & Johnson (JNJ)

Top Social Posts #

Top posts by engagements in the last XX hours

"In light of the current trade war and geopolitical uncertainties investing in the biotech sector is an attractive option. Here are a few quick investment ideas off the top of my head. Additions are welcome of course. $PTGX Interesting pipeline (including oral IL-23R /1"
X Link @GermanBiotech 2025-10-31T21:59Z 3105 followers, 1018 engagements

"$ABVX - Some additions and corrections: 1) The (persistent) pursuit of testing ABX464 (obefazimod) for the indication of UC is thanks to former CEO Ehrlich not gastroenterologists Sandberg and Vermeire. IMO Ehrlich's achievement is not adequately recognized"
X Link @GermanBiotech 2025-07-23T17:09Z 3105 followers, 2554 engagements

"antagonist and oral IL-17 inhibitor). Acquisition by $JNJ is highly likely. $ZYME Upcoming readout of the HERIZON-GEA-01 Phase X study (zanidatamab in 1L Her2+ GEA). Clinical validation of $ZYME's new ADC technology recently successful ( ZW191). /2"
X Link @GermanBiotech 2025-10-31T22:00Z 3105 followers, XXX engagements

"Peptidream (Tokyo Stock Exchange) Often overlooked (and consequently undervalued) leading company in peptide therapy with many valuable collaborations with international pharmaceutical companies. /3"
X Link @GermanBiotech 2025-10-31T22:01Z 3105 followers, XXX engagements

"$PFE with its latest strange press release. It reminds me of a screaming child lashing out wildly. As for $NVO's alleged market dominance I recommend reading the latest quarterly report from $LLY. $MTSR"
X Link @GermanBiotech 2025-10-31T20:53Z 3101 followers, XXX engagements

"$ATNM Promising ARCs but poor management. In Q4 results are expected on conditioning with Iomab-ACT prior to BMT/GeneTx in sickle cell disease among other things. /4"
X Link @GermanBiotech 2025-10-31T22:02Z 3105 followers, XXX engagements

"I am currently looking at Peptidream $PPTDF a Japanese biotech company that develops therapeutic and diagnostic peptides. Interesting pipeline (overview attached) cooperations with many international pharmaceutical companies and - very unusually - profitable for years. /1"
X Link @GermanBiotech 2025-07-07T18:49Z 3100 followers, 1763 engagements

"Peptidream $PPTDF earns the money for its own drug research with these marketed diagnostic radiopharmaceuticals. In addition there are payments from multiple international pharmaceutical companies for which Peptidream develops therapeutic peptides. /3"
X Link @GermanBiotech 2025-07-07T18:59Z 3100 followers, 1005 engagements

"Peptidream $PPTDF shares are traded on the Tokyo Stock Exchange. Has anyone taken a closer look at the company Comments are always welcome. I will take a closer look at the patents over the next few days. /4"
X Link @GermanBiotech 2025-07-07T19:07Z 3100 followers, XXX engagements

"@dedwng I don't see it that way. X. $NVO is no longer THE dominant player (see $LLY as well as the numerous competing products from other companies that will be coming onto the market in the foreseeable future). X. The claim that $NVO would halt $MTSR's development candidates /1"
X Link @GermanBiotech 2025-10-31T21:57Z 3101 followers, XXX engagements

"@dedwng after a possible takeover is completely unfounded at this point in time. X. It bothers me when companies promote free market economics but when their own interests are affected they are quick to call for government regulation. /2"
X Link @GermanBiotech 2025-10-31T21:58Z 3101 followers, XX engagements

"It is interesting to see how sensitive a global pharmaceutical company like $PFE is to a legitimate takeover bid from a competitors such as $NVO. Even the MAGA card is being played. Ridiculous $MTSR"
X Link @GermanBiotech 2025-10-30T11:20Z 3101 followers, 1336 engagements

"$XNCR In the past it had many lucrative out-licensing deals (which is why its balance sheet still shows a strikingly low accumulated deficit) but then went through a prolonged phase of less successful development projects. Now $XNCR appears to have developed a promising /5"
X Link @GermanBiotech 2025-10-31T22:02Z 3101 followers, XXX engagements